617 related articles for article (PubMed ID: 25619125)
1. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
[TBL] [Abstract][Full Text] [Related]
2. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Jones LE
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
[TBL] [Abstract][Full Text] [Related]
3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
6. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
Akl EA; Kahale L; Sperati F; Neumann I; Labedi N; Terrenato I; Barba M; Sempos EV; Muti P; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD009447. PubMed ID: 24966161
[TBL] [Abstract][Full Text] [Related]
8. Safety and low molecular weight heparin in older people in a hospital with ambulatory care.
Chan DK; Ong B; Almafragy H; Karr M; Hung AW; Liu JG
Arch Gerontol Geriatr; 2006; 43(2):233-41. PubMed ID: 16359739
[TBL] [Abstract][Full Text] [Related]
9. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
Akl EA; Labedi N; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Nov; (11):CD009447. PubMed ID: 22071865
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis.
Ishi SV; Lakshmi M; Kakde ST; Sabnis KC; Jagannati M; Girish TS; Jeyaseelan L; Cherian AM
J Assoc Physicians India; 2013 Dec; 61(12):882-6. PubMed ID: 24968543
[TBL] [Abstract][Full Text] [Related]
13. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Perini E; Penholati RR; Carvalho MG
Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
[TBL] [Abstract][Full Text] [Related]
14. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
15. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
[TBL] [Abstract][Full Text] [Related]
16. Suboptimal management of unfractionated heparin compared with low-molecular-weight heparin in the management of pulmonary embolism.
Khor YH; Smith R; McDonald CF
Intern Med J; 2014 Apr; 44(4):339-44. PubMed ID: 24877250
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
18. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Safety between Different Kinds of Heparins in Patients Receiving Intra-Aortic Balloon Counterpulsation.
Guan X; Chen M; Li Y; Zhang J; Xu L; Sun H; Zhang D; Wang L; Yang X
Thorac Cardiovasc Surg; 2021 Sep; 69(6):511-517. PubMed ID: 32998166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
